The study of FDG PET-CT on the value in predicting of patient outcome after treatment of stage III non-small cell lung cancer

Abstract

7572 Background: Up to the present study, the value of FDG PET-CT in patients of non-small cell lung cancer (NSCLC) before and after treatment has been approved. However, the significance of FDG PET-CT during the treatment has not been confirmed. The objective of this study was to evaluate 18FDG PET-CT for assessment of therapy response and prediction of patient outcome after concurrent chemo-radiotherapy (CCRT) of NSCLC. Methods: Forty six patients with histologically proven stage III NSCLC had two repeated FDG PET-CT scans either one week before therapy and at the dose of 40∼50Gy, the SUVmax and Changes of the two group after completion of NARCT were compared with (1) the therapy response and (2) treatment results and long-term survival. Results: Of the 46 eligible patients, the pretreatment SUVmax of the responding and nonresponding groups was7.59±3.14 and 14.72±4.67 respectively. The midtreatment SUVmax of the two groups was 2.89±1.39 and 9.82±3.31 respectively. Significantly difference (t= 4.74,P=0.001; t=7.23,P=0.001) in SUVmax were observed either before and during treatment. Furthermore, the percent change of SUVmax of pretreatment and midtreatment was ΔSUVmax=61.91±86.69 and ΔSUVmax=33.56±90.37, difference between the two groups was also significantly (t=2.83, P=0.007). In addition, the 1 year survival rate of the the respond and non-respond group were 73% and 69% respectively, the 2-year survival rate of the two groups were 40% and 37% respectively, significant difference was observed between the two groups (P=0.001; P=0.001). Conclusions: 18FDG PET-CT is highly effective in detecting therapy response in stage III NSCLC patients, the analysis of percent change of SUVmax provides incremental value in early prediction of therapy response and patient outcome. No significant financial relationships to disclose.